Introduction
The World Health Organization (WHO, 2002) defines endocrine disruptors (EDs) as, "Exogenous substances that alter function(s) of the endocrine system and consequently cause adverse health effects in an intact organism or its progeny, or (sub)populations." Currently, the European Commission (EC) is developing a set of criteria for the identification of such endocrine-disrupting substances that requires regulatory action. At this time, EDs are identified on a case-by-case basis using the available guidance provided in Organization for Economic Co-operation and Development (OECD) Guidance Document 150 (GD 150; OECD, 2012) . The OECD Conceptual Framework for Testing and Assessment of Endocrine Disruptors provides a tiered framework for organization of study information to assess endocrine activity. This framework is not intended to be a regulatory testing strategy, but to provide guidance in prioritizing relevant data streams and methods according to the type and level of information needed for a regulatory assessment. In the United States, the U.S. Environmental Protection Agency's (EPA's) Endocrine Disruptor Screening Program (EDSP) has been designed to evaluate the endocrine activity of selected substances in a two-tiered testing approach: Tier 1 assays for screening potential endocrine activity, with the focus not on the identification of adverse effects, and Tier 2 studies in non-mammalian and mammalian species that include dose-response changes in apical endpoints to evaluate the potential for a substance to cause adverse responses due to a disruption in a specific endocrine pathway. Both the OECD guidance on evaluating endocrine disrupting properties and the EPA's EDSP are currently under review at this time with changes to focus on data interpretation and alternative methods used to evaluate endocrine activity of a substance.
Perfluorinated compounds are surface active agents that have been used in coatings for packaging, carpets, leather products, and textiles. Among the perfluoroalkyl acids (PFAAs), the 8-carbon (C8) perfluorooctanoic acid (PFOA) and perfluorooctane sulfonate (PFOS) have been the most extensively studied, and both are currently on EPA's List 2 of substances identified by EPA to be screened for endocrine activity. However, concerns have been raised over the toxicity and https://doi.org/10.1016/j.yrtph.2018.09.001 Received 13 June 2018; Received in revised form 31 August 2018; Accepted 1 September 2018 bioaccumulation of these long-chain perfluorinated compounds (C8 and longer), fueling the search for and development of alternative fluorinated compounds consisting of shorter carbon chains. The effort to eliminate the use of PFOA and higher perfluoroalkyl carboxylic acid (PFCA) homologues (USEPA, 2006) has led to the increased use of C6 fluorotelomer compounds that serve as replacements for the C8 compounds (USEPA, 2013 ).
An impurity, metabolite and or degradation product of C6-fluorotelomer compounds is perfluorohexanoic acid (PFHxA) (Fig. 1) . Levels of PFHxA measured in the environment and in human biomonitoring studies are rarely due to direct exposure to PFHxA itself. PFHxA has been identified in the environment based on the transformation of these mixed-chain-length telomers and also as one of their metabolites identified in exposed mammalian species (Rice, 2015; Russell et al., 2015) . Mulkiewicz et al. (2007) demonstrated in vitro that longer perfluorocarbon chain length the greater the toxicity, with PFHxA having the lowest toxicity compared to C8eC10 perfluorinated carboxylic acids. However, based on the potential concern regarding the toxicological effects of PFHxA, a number of guideline studies have been conducted in rats and mice (Chengelis et al., 2009; Klaunig et al., 2015) . PFHxA did not cause any reproductive, developmental, or toxic or carcinogenic effects following sub-chronic and chronic repeated-dose administration in rats or mice; however, since there are concerns with polyfluorinated chemicals (PFCs) in general, it was of interest to determine whether there was any potential endocrine activity associated with exposure of humans and/or wildlife to PFHxA. Given the concern regarding endocrine activity of longer-chain-length PFCAs, the fact that fluorotelomer acrylates are metabolized or transformed in the environment to PFHxA, there was a need to evaluate the potential of PFHxA to have endocrine activity, and to determine whether it also has endocrine-disrupting (ED) properties according to the WHO definition (WHO, 2002) .
To assess potential ED properties of PFHxA, the published studies in the literature, and available unpublished toxicology study reports, were evaluated to identify endocrine activity of PFHxA across the estrogen (E), androgen (A), thyroid (T), and steroidogenesis (S) pathways. This assessment was conducted by evaluating the endocrine activity of PFHxA in in vitro assays and in mammalian and non-mammalian in vivo studies, to assess the potential alteration in the function of the endocrine system that results in adverse health effects in an intact organism.
Approach and findings
To evaluate the overall endocrine activity of PFHxA, we conducted a comprehensive literature search to capture relevant peer-reviewed literature, along with direct hand-searching to ensure identification of all critical toxicology studies that include endocrine endpoints. Studies are presented according to three categories: in vitro, in vivo mammalian, and in vivo non-mammalian. These studies were reviewed by evaluating their quality and relevance for assessing endocrine activity, along with identifying and extracting endocrine-specific endpoints across the estrogen (E), androgen (A), thyroid (T), and steroidogenesis (S) pathways. In vitro data captured from the peer-reviewed literature, as well as highthroughput screening (HTS) assays within the ToxCast/Tox21 database (USEPA, 2016), were integrated into this assessment. Endocrine endpoints extracted from these studies were ranked to facilitate a weightof-evidence (WoE) analysis across eight endocrine hypotheses, as defined by Borgert et al. (2014) and discussed in Section 3.6 (see also  Tables 5-12 ). The ranking of endocrine endpoints, as defined by Borgert et al. (2014) , was based on the strength of these endpoints to interpret the significance of any potential endocrine activity.
Peer-reviewed literature search and study identification
A comprehensive literature search was conducted to confirm that all relevant in vitro and in vivo mammalian and non-mammalian (ecotoxicology) studies in the peer-reviewed literature would be captured to evaluate the endocrine activity of PFHxA (Table 1) . To execute the search, syntax unique to each database queried (i.e., PubMed and Embase) was developed in which all relevant chemical identification (e.g., synonyms and registry numbers), endocrine pathways, general toxicity, and carcinogenesis key words were captured. This syntax was reviewed by endocrine and ecotoxicology experts prior to implementation of the search.
The resulting published literature was reviewed and organized to meet two objectives: (1) To identify studies reporting data relevant to the evaluation of PFHxA in the context of the E, A, T, and S pathways (primary objective), and (2) identify studies that contain contextual information relevant to the primary objective, such as toxicokinetics, review articles, and evaluations of similar substances (secondary Borghoff et al. Regulatory Toxicology and Pharmacology 99 (2018) 168-181 objective). To ensure that all relevant data were captured to inform both the primary and secondary objectives, we also conducted "hand searching" to identify studies that might have been missed and include any unpublished toxicology study reports that warrant consideration. Query outcomes from both PubMed and Embase were merged and duplicates eliminated, resulting originally in 158 records to be reviewed for context. Hand-searching identified eleven additional studies which included several mammalian studies in which sodium perfluorohexanoate (NaPFHx) [CAS # 2923-26-4] and ammonium salt of perfluorinated hexanoic acid (APFHx) [CAS # 21615-47-4] was evaluated. The toxicity of these salts were incorporated to represent the toxicity of PFHxA, because the pKa of PFHxA is less than 3, and it exists in the environment principally as an anion. An updated search (May 31, 2018) , identified nineteen additional results that were merged with the previous results for a total of 177 results (Fig. 2) .
Studies were then screened by title and abstract and sorted into six categories: (1) analytical methods, (2) exposure information, (3) contextual information and PFHxA-specific information and data on endocrine-responsive endpoints, (4) in vivo non-mammalian studies, (5) in vivo mammalian studies, and (6) in vitro assays. The majority of the excluded studies were assigned to a category of either analytical methods (1) or providing information on exposure (2) and, as such, were not used for this review. Studies that did not evaluate PFHxA or endocrine information used to inform activity across the E, A, T, or S pathways were also excluded.
During the title and abstract-level screening, 20 peer-reviewed articles and or study reports were identified as relevant to an assessment of PFHxA endocrine activity and were advanced to full-text review and data extraction. These cited references comprise four in vivo nonmammalian studies, ten articles containing in vitro assays, and seven in vivo mammalian studies. In some instances, the references contained multiple models or assays within the article (i.e., in vitro and in vivo); these were reviewed separately.
High-throughput screening (HTS) database
In vitro high-throughput screening (HTS) data for PFHxA were available through the ToxCast/Tox21 consortium, a federal collaboration between the National Toxicology Program at the National Institute of Environmental Health Sciences and the National Center for Advancing Translational Sciences, the Food and Drug Administration, and the EPA. Processed ToxCast/Tox21 data were extracted from two resources: (1) EPA's Endocrine Disruption Screening Program for the 21st Century (EDSP21) Dashboard (USEPA, 2017), and (2) the EPA's summary files (invitrodb_v2, released Oct 2015) (USEPA, 2016) .
Assay-specific HTS data pertaining to androgen receptor (AR), aromatase activity, estrogen receptor (ER), and thyroid receptor (TR) were extracted from EPA's summary files (Supplemental data, Appendix B, Table B -13.) . Chemical-assay activity was characterized by hit calls, represented by values of 1, 0, or −1. A value of 1 indicated an "active" chemical, a value of 0 indicated an "inactive" chemical, and a value of −1 indicated that the activity could not be determined. Hit calls were based on criteria previously defined by EPA (Judson et al., 2016) . These model scores take into account potential assay interference produced by cytotoxicity.
The total numbers of assays used to determine whether PFHxA has ER, AR, TR, or aromatase activity, along with the number of assays that showed bioactivity, are provided in Table 2 . Overall, PFHxA was inactive in all of the assays identified. The EDSP21 Dashboard also includes integrated parameters that predict AR and ER bioactivity. Specifically, area under the curve (AUC) values were extracted from the database, which are model scores that predict AR or ER agonist, antagonist, and inactive chemicals with high sensitivity and specificity (Browne et al., 2015; Judson et al., 2015) . AUC values integrate the activity among ToxCast/Tox21 AR or ER assays and result in values ranging from 0 to 1. AUC values of 0 indicate inactivity, and values of 1 indicate full agonist or antagonist activity. These model scores also integrate potential assay interference produced by cytotoxicity. For PFHxA, the overall evaluation of integrated data sets per endocrine pathway activity using a model described by Judson et al. (2015) provided an AUC of 0 for both ER and AR, confirming no activity along either the E or A pathways.
Study quality assessment
The peer-reviewed articles and study reports identified for data extraction were reviewed for study quality and data reliability using the software-based tool "ToxRTool" (Toxicological data Reliability Assessment Tool; (https://eurl-ecvam.jrc.ec.europa.eu/about-ecvam/ archive-publications/toxrtool) (Schneider et al., 2009 ). Development of the ToxRTool was supported by the European Union Reference Laboratory for alternatives to animal testing (EURL-ECVAM) and provides the ability to evaluate various types of studies, experimental data, and endpoints within the Klimisch categories of 1, 2, or 3 (a score of 1 means reliable without restrictions; 2, reliable with restrictions; and 3, not reliable due to significant methodological or documentation deficiencies [Klimisch et al., 1997] ). A category of 4, not assignable, was Fig. 2 . PFHxA studies identified across assay categories (i.e., in vivo nonmammalian, in vivo mammalian, and in vitro) used for extracting endocrine endpoint activity. The number of peer-reviewed articles and study reports (cited references used for data extraction) differs from the number of studies/ assays identified in each assay category because multiple studies/assays were reported in selected cited references. Searches were performed on 1/25/2017 and 9/21/2017 with recent updating on 5/31/18. This figure includes the final numbers of articles identified following merging both searches. One of the four in vivo non-mammalian studies and one of the seven in vivo mammalian studies are study reports that were used for this comprehensive review of the effects of PFHxA in these models. Borghoff et al. Regulatory Toxicology and Pharmacology 99 (2018) [168] [169] [170] [171] [172] [173] [174] [175] [176] [177] [178] [179] [180] [181] not used in the evaluation. This tool provides a means to document the study quality with sufficient transparency to support the decision process and at the same time generate a record of this documentation per study. Although a Klimish score of 2 encompasses a range in study quality, the ToxRTool provides a mechanism to document specific quality characteristics that can be referenced when integrating the overall findings. These assessments were conducted for each study reviewed per assay category (in vivo and in vitro), considering that some individual scientific articles would report multiple types of studies (e.g., in vivo and in vitro in one study) within these categories. For each study identified for full review and data extraction, a ToxRTool data sheet with quality score is provided in Supplementary Data-Appendix A.
The study quality score is also listed in Tables 3 and 4 for the relevant studies identified, to provide endpoint information for evaluating PFHxA endocrine activity. Endpoints per endocrine pathway were extracted from all studies identified, but the quality of the study was considered in the overall interpretation of the WoE analysis, as described below. Guideline studies that incorporate standardized and validated test methods and that were conducted under Good Laboratory Practices (GLP) generally c Not scored using the ToxRTool but assumed to be at least a quality score of 2 based assay conduct.
Table 4
PFHxA in vivo mammalian and non-mammalian studies: Study quality and relevance with endpoints assessed per endocrine pathway.
Study Type/Level Endpoints Assessed Quality Score
Peer-Reviewed Study/ Toxicology Study Report
Mammalian -Level 1 and 4 methods
Combined repeated-dose toxicity study (28-day) with reproduction/developmental toxicity screening OECD TG 422 -rats -Level 4
Estrogen, Androgen, Thyroid, Steroidogenesis S.J. Borghoff et al. Regulatory Toxicology and Pharmacology 99 (2018) 168-181 provide the highest confidence in the data reviewed, based on the required documentation along with required quality control assessment of the data. However, non-guideline studies that were not conducted under GLP and peer-reviewed publications also provide critical information for the overall assessment, especially when the data set for a specific chemical is limited, as is the case for PFHxA non-mammalian studies. Overall, the final quality score is based on the information provided in the publication and/or study report. Although the HTS data obtained in the ToxCast/Tox21 database are not easily scored according to the criteria in the ToxRTool, these assays are assumed to have at least a quality score of 2, based on the dose-response analysis and the incorporation of cytotoxicity findings in the determination of activity, such that they were considered in the overall WoE analysis.
Although not part of the study quality assessment, these studies were also identified within the OECD Conceptual Framework for Testing and Assessment of Endocrine Disruptors (OECD, 2012), as one of five levels of information considered:
Level 1: Existing data and non-test information, including all available eco-toxicological data from standardized or non-standardized tests. Level 2: In vitro assays providing data about selected endocrine mechanism(s) or pathways(s) (mammalian and non-mammalian methods). Level 3: In vivo assays providing data about selected endocrine mechanism(s) or pathways(s) for both mammalian and non-mammalian models. Some of these assays may provide evidence of adverse effects. Level 4: In vivo assays providing data on adverse effects on endocrine-related endpoints, where effects can be sensitive to more than one mechanism and may be due to non-ED mechanisms. Level 5: In vivo assays providing more comprehensive data on adverse effects on endocrine-relevant endpoints over more extensive parts of the life cycle of the organism, where effects can be sensitive to more than one mechanism and may be due to non-ED mechanisms.
Overall, the OECD Level of the method indicates the relevance of the data in the overall analysis and is considered to reflect the types of studies that are used to identify adverse responses, and methods that can provide information as to whether the mechanism (or mode) of action (MoA) involves alteration in an endocrine pathway to produce an adverse response. Therefore, MoA information is collected within the Level 1 and 2 methods and is useful primarily for prioritizing and informing MoA. Level 3 methods are used to screen activity in vivo and inform possible endocrine MoA or toxicological pathways. Study methods considered Levels 4 and 5 would provide information to characterize possible adverse effects at sensitive life stages and through life-cycle exposures. The method level designation assigned to each study was according to OECD Guidance 150 (2012) for analyzing the endocrine activity of PFHxA. Method levels are indicated in Tables 3  and 4 .
Study summaries and endpoint extraction

Study summaries by assay category
A summary of the studies is provided in Tables 3 and 4 ( i.e., in vitro, in vivo mammalian, in vivo non-mammalian) , and the overall findings are described below. Details on the endpoints extracted per study are provided in the Supplemental Data, Appendix B, Tables B1-B12.
In vitro assays
In a competitive binding assay, liver cytosol extracted from 17β-estradiol (E2)-exposed rainbow trout was used as the source of receptor, (Gorrochategui et al., 2014) . PFHxA did not inhibit this activity at non-cytotoxic concentrations up to 500 μM. PFHxA also did not inhibit aromatase activity in a transcription factor assay in MCF-7 cells reported within the ToxCast/Tox21 database (Table 2) .
PFHxA did not show antagonism in an AR transactivation (ARTA) assay (Chinese hamster ovary cells transfected with receptor pSVAR0 and reporter gene MMTV-LUC), with co-exposure to various concentrations of the androgen agonist R1881 (Rosenmai et al., 2016) . In MDA-kb2 cells, which have MMTV.luciferase.neo reporter gene construct and stably express androgen-and glucocorticoid-responsive luciferase reporter, AR agonist or antagonist activity was evaluated by exposing the cells to PFHxA (up to 100 μM)) without and with DHT, respectively. The positive control DHT was used to assess activation of the AR receptor in this assay. PFHxA did not activate the AR, however, PFHxA significantly enhanced DHT-stimulated AR activity at concentrations > 50 μM. Further analysis of AR activation was evaluated in LNCaP cells exposed to either PFHxA or DHT (positive control) to assess the expression of androgen responsive genes (e.g., PSA, NKX3-1 and TMPRSS2, induced by DHT or CDKN1A, inhibited by DHT). PFHxA exposure did not result in any response, induction or inhibition in androgen responsive genes. PFHxA did not show any AR bioactivity in a panel of nine AR HTS assays in which AR binding and agonist and antagonist transactivation activity was evaluated (Table 2 ; ToxCast/ Tox21 database).
Several steroidogenesis assays using human adreno-carcinoma cellline (NCIeH295R cells) were conducted according to the OECD Test Guideline (TG) 456. Exposure to PFHxA (concentrations up to 50 μM) was reported to have no effect on either estrogen, testosterone or S.J. Borghoff et al. Regulatory Toxicology and Pharmacology 99 (2018) 168-181 progesterone levels as reported by Rosenmai et al. (2016) . A more recent steroidogenesis assay conducted in H295R cells, in which cells were exposed up to 100 μM PFHxA, did not result in a change in the levels of estradiol, estrone, testosterone and progesterone in the cell media with a lack of impact on genes identified to be involved in steroidogenesis; CYP19A1, CYP21A2, CYP17A1, CYP11A1, STAR, and HSD3B (Behr et al., 2018) . A number of in vitro assays were conducted to evaluate the potential for PFHxA to interfere with the T pathway. Vongphachan et al. (2011) (CEN) and herring gull embryonic neuronal (HGEN) cells. These genes are involved either in the conversion pathway of the active (T3), low active (T4), or inactive (rT3/T2) forms of THs and were measured following exposure to PFHxA. PFHxA increased the expression of only three of these thyroidresponsive genes (D3, D2, and MBP) in primary cultures of CEN cells, and increased transcription factor Oct-1 at only the highest concentration in HGEN cells. In CEN cells, there was a significant increased expression in D2 but only at the highest exposure concentration of 10 μM, whereas the increased expression of D3 occurred at 3, but not 10 μM. The expression of MBP was increased with exposure to 10 μΜ PFHxA, with concentration-related responses from 1 to 10 μΜ. The changes noted were not consistently shown to be concentration dependent across genes in CEN cells. In H4IIE rat hepatoma cells incubated with 0.1-100 μM PFHxA for 72 h, there were no significant concentration-dependent changes in mRNA expression of Hex or Pax 8 (thyroid-responsive genes) related to the solvent controls, suggesting that PFHxA does not interfere in thyroid-related processes in this cell line (Naile et al., 2012) . Weiss et al. (2009) measured the ability of PFHxA to compete with T4 (thyroxine) for binding to human TTR in a competitive binding displacement assay using radiolabeled T4. PFHxA competed with T4 with a calculated IC 50 of 8220 nM compared to 61 nM for unlabeled T4, resulting in a relative potency (T4-REP factor) of 0.007 vs. 1 for T4. This suggested a weak interaction between PFHxA and TTR. Similar negative to weak binding was reported by Ren et al. (2016) for PFHxA to human TBG (IC 50 = not detected compared to T4 which was 44 nM)) and TTR (IC 50 = 3189 nM compared to T4 which was 31 nM) transport proteins.
PFHxA (various concentrations below cytotoxic levels) had no effect on protein intrinsic fluorescence in a fluorescence polarization-based competitive binding assay, suggesting that it does not bind or has very weak binding affinity to thyroid receptor (TR) α-ligand binding domain (LBD), along with no agonist or antagonist activity in a T-screen assay used to detect TR activity in GH3 rat pituitary cell cancer cells (Ren et al., 2015) .
In vivo mammalian studies
Multiple in vivo studies conducted in rodents were of high quality (score of 1 or 2) and provided endpoints relevant for evaluating the effects of PFHxA activity across the E, A, T, and S pathways (Kirkpatrick, 2005; Loveless et al., 2009; Chengelis et al., 2009; Iwai and Hoberman, 2014; Klaunig et al., 2015) . Since the pKa of PFHxA is < 3, it exists in the environment as the PFHx anion, therefore, the findings from selected toxicology studies that evaluated salts of perfluorohexanoate (Loveless et al., 2009; Iwai and Hoberman, 2014) were incorporated into the potential endocrine evaluation of PFHxA.
In a 28-day repeated-dose study, with reproductive and developmental toxicity screening, PFHxA was administered by oral gavage to male and female rats to evaluate male and female reproductive performance, such as gonadal function, mating behavior, conception, parturition, and early postnatal development (Kirkpatrick, 2005) . Dose levels of PFHxA were 0, 50, 150, and 450 mg/kg/day, but due to excessive toxicity noted at 450 mg/kg-day, the level was lowered to 300 mg/kg/day on study day 4. Male rats received 14 daily doses prior to mating and were dosed throughout the mating period through the day prior to euthanasia; in total, males received 35 doses. Females received 14 daily doses prior to mating, with dosing through lactation day 3, for a total of 39-44 doses. Although there was evidence of overt toxicity in the 450/300-mg/kg/day dose group, reproductive performance, precoital interval, and gestation length were unaffected with administration of PFHxA. The authors also noted that endpoints reflective of E, A, T, and S pathways were unaltered in this study.
In a 90-day toxicity study, male and female Sprague-Dawley rats were administered PFHxA by oral gavage at dose levels up to 200 mg/ kg/day (Chengelis et al., 2009 ). Body-weight gains were lower in male rats administered 10, 50, and 200 mg/kg/day compared to controls, and this was observed throughout dosing with liver toxicity at the highest dose level supported by changes in clinical chemistry endpoints, increased liver weights, and changes in liver histopathology, and minimal centrilobular hepatocellular hypotrophy. These changes were used to identify a no-observed-adverse-effect level (NOAEL) for oral administration of 50 mg/kg/day for male and 200 mg/kg/day for female rats. Key to this investigation was the lack of changes in endpoints that reflect endocrine activity across the E, A, T, or S pathways, as identified in the endpoints extracted in the summary tables presented in the Supplementary Data (Appendix B) and referenced in the ranking tables per endocrine hypothesis in Tables B2-B7 Loveless et al. (2009), reported a 90-day toxicity study and a onegeneration reproduction and developmental study with sodium perfluorohexanoate (NaPFHx) (CAS # 2923-26-4) in male and female Sprague-Dawley rats. In the 90-day study, rats were administered NaPFHx daily by gavage at dose levels of 0-500 mg/kg/day, with inclusion of a 30-and 90-day recovery group. The NOAEL in the 90-day study was determined to be 20 mg/kg/day based on a nasal lesion observed at the 100-and 500-mg/kg/day dose levels. Similar to PFHxA (Chengelis et al., 2009 ), high-dose administration of NaPFHx showed increases in liver weights with mild hepatocellular hypertrophy. However, the only endocrine-associated endpoint identified following administration of NaPFHx to rats was a minimal change in thyroid weight in female rats at the highest dose, noted only in the recovery group, with minimal hypertrophy of thyroid follicular epithelium in male and female rats in the 500-mg/kg-day group, and in only one male rat that was administered 100 mg/kg-day at the end of the 90-day repeated dosing. Following 30 days of recovery, there was still minimal follicular cell hypertrophy present in the 500-mg/kg-day animals, with the similar incidence noted at the end of the 90-day dosing period. As discussed by the authors, the thyroid changes were minimal and were proposed to be secondary to receptor-mediated up-regulation of liver metabolic enzymes. Based on an increase in liver weight, this effect may have been induced, because thyroid hypertrophy tends to be a common finding in rats with induction of hepatic microsomal enzymes (Capen, 1994) . The toxicology profiles of PFHxA and NaPFHx were complimentary with minor differences noted considering different dose level potential for pH changes influencing the level of PFHx anion present in tissues.
Also reported by Loveless et al. (2009) were reproductive evaluations in rats orally dosed with NaPFHx at the same dose levels as the 90-day study. In this reproductive study, rats were orally administered NaPFHx for approximately 70 days prior to cohabitation, through gestation and lactation, for a total of about 4 months. No NaPFHx-related effects were observed on any reproductive parameters, with a NOAEL of 20 mg/kg/day identified in P1 adult rats based on reduced body weight, and a NOAEL of 100 mg/kg/day for reproductive toxicity that was based on effects limited only to reduced F(1) pup weights. In the developmental study, female rats were dosed (0, 20, 100, and 500 mg/ kg/day) via gavage on gestation days (GDs) 6-20. The maternal and
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Regulatory Toxicology and Pharmacology 99 (2018) [168] [169] [170] [171] [172] [173] [174] [175] [176] [177] [178] [179] [180] [181] developmental toxicity NOAEL was 100 mg/kg/day based on maternal and fetal body weight effects at 500 mg/kg/day. NaPFHx is therefore concluded not to present a reproductive or developmental hazard. In both studies described by Loveless et al. (2009) , there were no changes in endocrine endpoints to suggest alterations in the E, A, T, or S pathways (Appendix B, Supplemental Tables B2-B7). A 2-year toxicology and carcinogenicity study was conducted in male and female Sprague-Dawley rats orally gavaged PFHxA (7 days per week) at dose levels of 0, 2.5, 15, and 100 mg/kg/day (males) or 5, 30, and 200 mg/kg/day (females) (Klaunig et al., 2015) . There was no evidence of tumor induction associated with the administration of PFHxA, with only histological changes restricted to the kidneys in female rats in the highest dose group. Of critical importance to this evaluation was that no histopathological changes were observed in endocrine-sensitive tissues such as ovaries, thyroid, prostate, pituitary, testes, or uterus. Also, at 26 and 52 weeks of exposure to PFHxA, there were no statistically significant alterations in estradiol, luteinizing hormone (LH), or testosterone blood levels at any dose level compared to the control groups.
The effects of ammonium salt of perfluorinated hexanoic acid (APFHx) [CAS # 21615-47-4] were evaluated in pregnant CD1(ICR) mice as reported by Iwai and Hoberman (2014) . Female rats were administered APFHx or vehicle control orally from GD 6 through 18. In the first phase of this study, the dose levels were 0, 100, 350, and 500 mg/kg/day, but excess mortalities and adverse clinical symptoms were observed that resulted in a decrease in dose levels under phase 2 (0, 7, 35, and 175 mg/kg/day). Parameters evaluated include mortality, viability, body weights, clinical signs, abortions, premature deliveries, pregnancy and fertility, litter observations, maternal behavior, and sexual maturity in the F1 generation. In phase 2, adverse effects occurred only in the 175 mg/kg/day group and consisted of increased stillborn pups, pups dying on postpartum day (PPD) 1, and reduced pup weights. Based on these data, the maternal and reproductive NOAEL of APFHx was set to 100 mg/kg/day. In this study, there were no changes in endocrine-sensitive endpoints used to evaluate the endocrine activity of APFHx across the E, A, T, or S pathways.
We identified two human studies in the peer-reviewed literature that did not provide clear study outcome information on hormone-level changes that could be correlated to PFHxA exposure, and these were considered to be low-quality studies (Zhou et al., 2016; Li et al., 2017) . In the Zhou et al. (2016) assessment, 225 Taiwanese adolescents aged 13-15 years were investigated during 2009-2010 for a relationship between serum PFHxA and reproductive hormone concentrations (estradiol and testosterone) in a cross-sectional study design. Concentration of PFHxA in serum ranged from 0.1 to 0.3 ng/mL in both boys and girls. The level of testosterone, but not estradiol, was negatively associated with serum PFHxA concentration. However, because multiple poly-and per-fluoroalkyl substances (PFASs) were measured in these adolescents' serum, a direct association between PFHxA and these changes in hormone levels cannot be established.
This same concern applied to the study reported by Li et al. (2017) , in which PFHxA levels, along with those of several PFASs, were measured in serum samples of participants in southern China ranging from 1 month to 90 years of age, and of both sexes. Five thyroid hormone levels; (TSH, free T4, Free T3, thyroglobulin antibodies (TGAb), and thyroid microsomal antibody (TMab) were measured to correlate to the measured levels of PFAS. PFHxA was significantly positively correlated with TGAb and TMAb in all samples, but again, it is difficult to differentiate the significance of this change considering that seven other PFAS were also measured. Therefore, the changes noted in both of these studies, though important, do not provide clear evidence of endocrine activity in the population with measured levels of PFAS in their blood.
Based on the studies that provided Rank 1, 2, or 3 endpoints across the eight hypotheses evaluated, PFHxA (or NaPFHx or APFHx) or did not show any activity in the E, A, T, or S pathways.
In vivo non-mammalian studies
A Frog Embryo Teratogenicity Assay (FETAX)-Xenopus laevis, which contains some study design attributes that are similar to the Amphibian Metamorphosis Assay (AMA), was conducted by Kim et al. (2015) . Fertilized Xenopus embryos were dosed with 0.1-2.0 mM PFHxA in dimethyl sulfoxide (DMSO). While a standard FETAX assay is 96hr in exposure duration (NTP, 2000) , it is unclear the exact exposure duration in the Kim et al. (2015) study as reference is made to an exposure duration of 10d in sections of the manuscript. PFHxA exposure was associated with reduced head-to-tail length with the study LC 50 of 1524 μM. Reduced head-to-tail length is considered a Rank 3 endpoint for evaluating a substance as a thyroid agonist. The EC 50 for malformations was 1047 μM, while the minimum concentration that inhibited growth was 412 μM. However, no other specific measures of thyroid activity were either ranked or suggested an alteration in the T pathway. Furthermore, the authors speculate that the observed effects were due to phosphorylation of extracellular signal-regulated kinase (ERK) and c-Jun N-terminal kinase (JNK). While the study provides some apical growth data, the effective concentrations are approximately ¼ the LC 50 and may represent overt toxicity to the organism.
To further evaluate possible effects of PFHxA on the T pathway, Cassone et al. (2012) dosed fertilized Gallus gallus eggs with 9.7-9700 ng/g PFHxA in DMSO. PFHxA did not alter plasma T4 levels, pipping success, or morphology in exposed chickens, with no change in liver weight at any treatment level. In addition, several key mRNA transcripts associated with the T pathway were evaluated, and none were significantly affected by exposure to PFHxA. The concentration of PFHxA did increase in the liver, yolk sac, and cerebral cortex in a dosedependent fashion. The stock dosing solutions for this study were verified analytically which provided confidence in the finding that there was no equivocal evidence of T modulation in PFHxA-exposed chickens. As such, the changes in T responsive genes in PFHxA-exposed CEN and HGEN cells described previously (Vongphachan et al., 2011) , are not shown in this in vivo study to cause adverse effects on the development and survival of the embryo.
In a fish study that contained some study design attributes of a Fish Short-Term Reproduction Assay (FSTRA), Benninghoff et al. (2011) exposed juvenile rainbow trout to 250 ppm of PFHxA via the diet for 14 days. There were no statistically significant difference in plasma VTG levels in the exposed group relative to controls. While 11 month old juvenile trout were used, Vizziano et al. (2007) reported that sexual differentiation for rainbow trout begins around 5 weeks indicating that the fish utilized in this study were likely a mix of males and females. These data provide no equivocal evidence of in vivo estrogen modulation by PFHxA in fish.
A FSTRA study was conducted in Japanese medaka at aqueous concentrations of perfluorohexanoic acid, ammonium salt (PFHxA-NH 4 ) [CAS No. 21615-47-4] or the sodium salt (PFHxA-Na) [CAS No. 2923-26-4 ] at concentrations of 10 and 100 mg/L (CERI 2015) . No significant differences relative to controls were observed in medaka fecundity, fertility, survival or vitellogenin with either PFHxA-salt. Gonadal histopathology and genetic sex determination were not assessed in this study. However, these data support the findings of Benninghoff et al. (2011) that PFHxA does not cause in vivo modulation of the estrogen pathway in fish.
Also critical to this assessment was the conduct of a 21-week OECD TG 206 bobwhite quail reproductive study with PFHxA was conducted and described in a report provided by Frey et al. (2010) . There were no treatment-related effects at PFHxA dose levels of ≤10,000 mg/kg. Endpoints in this study included adult health, body weight, feed consumption, number of eggs laid, fertility, embryo viability, hatchability, offspring survival, and egg shell thickness were evaluated. This study followed a standardized protocol, was completed according to GLP and was conducted over 21 weeks. While the study did not measure mechanistic endpoints associated with endocrine modulation (e.g. steroid S.J. Borghoff et al. Regulatory Toxicology and Pharmacology 99 (2018) 168-181 levels, gene transcription), it did measure one of the most important apical endpoints associated with endocrine disruption (i.e., reproduction); therefore, the Frey et al. (2010) study did not show any changes in the most appropriate apical endpoint data (Appendix B, Supplemental Tables B8-B12) , suggesting a lack of endocrine activity across the E, A, and T pathways following administration of PFHxA at the doses evaluated.
Endpoint extraction per endocrine pathway
There are several source references that can be used to guide the identification and extraction of endpoints from differing types of studies that reflect E, A, T, or S endocrine pathway activity. These references include the OECD conceptual endocrine framework (OECD, 2012) and a white paper from the ACC Center for Endocrine Screening and Testing and Endocrine Policy Forum (EPF) (ACC and EPF, 2014) . The templates per endocrine pathway were provided in these references, were modified in this evaluation to include study-specific information, and are provided in the Supplementary Data, Appendix B, for each study category (in vitro, in vivo mammalian and in vivo non-mammalian) to provide the study-specific information used to highlight ranked endpoints per endocrine hypothesis for WoE analysis, as described in the next section.
Although it appears that many of the regulatory study reports are published in the scientific literature, it was necessary in some cases to review the full toxicology report when available, because the scientific article may not have included sufficient detailed reporting on endocrine endpoints to allow for a more complete evaluation. Endpoints identified as reflecting endocrine activity across the E, A, T, and S pathways were extracted for each of the in vivo studies identified, and the detailed results are provided in Supplementary Data, Appendix B, Tables  B3-B12 , where the information is provided for the E and A agonist and antagonist activity, along with endpoints that represent activity across the thyroid and steroidogenesis pathway.
Hypothesis-driven WoE analysis across endocrine pathways
As described by Borgert et al. (2014) and applied in various assessments, including one that described mainly Level 4 study types (De Peyster and Mihaich, 2014) , a hypothesis-driven WoE analysis was conducted for PFHxA based on the ranking of endocrine endpoints from Level 1 to Level 4 studies across eight endocrine hypotheses. These eight hypotheses include evaluating the potential of PFHxA to act as (1) an estrogen agonist, (2) an estrogen antagonist, (3) an androgen agonist, (4) an androgen antagonist, (5) a thyroid agonist, (6) a thyroid antagonist, (7) an inducer of steroidogenesis, and/or (8) an inhibitor of steroidogenesis.
As described by Borgert et al. (2014) , the endpoint ranks are defined as follows:
Rank 1: The endpoints are specific and sensitive for the hypothesis, are interpretable without knowing the responses of other endpoints, and are in vivo measurements rarely confounded by artifacts or nonspecific activity. Rank 2: The endpoints are specific and sensitive for the hypothesis, and are interpretable without knowing the responses of other endpoints, but are less informative than Rank 1, often due to potential confounding influences; includes in vitro and in vivo endpoints. Rank 3: The endpoints are relevant for the hypothesis, but only when they corroborate Rank 1 and 2 endpoints; includes some in vitro and many apical in vivo endpoints.
Tables 5-12 summarize the endpoints that were ranked across all eight hypotheses. Rank 1 endpoints, which would carry the most weight very evaluating endocrine activity, are mainly identified in Level 3 methods (OECD, 2012). Because PFHxA was not evaluated in Level 3 methods, the majority of the endpoints were either Rank 2 or 3, with several exceptions. In one non-mammalian study (Benninghoff et al., 2011 ) that contained study design attributes similar to the Fish ShortTerm Reproduction Assay (FSTRA), vitellogenin (VTG) concentration was measured, which has been designated as a Rank 1 endpoint for evaluation of estrogen agonist activity. In this particular study even though it was noted that there was an increase in VTG, the change was not significant in PFHxA exposed fish relative to controls. Furthermore, the non-significant increase in VTG was orders of magnitude less than the positive control estradiol, which was exposed at a fraction of the PFHxA concentration. In addition, a recently completed OECD 229 FSTRA study reported no change in medaka VTG levels relative to controls at a maximum aqueous concentration of 100 mg/L, further confirming that PFHxA does not modulate the estrogen pathway in vivo.
Considering the limited number of Rank 1 endpoints in this evaluation, the emphasis was on endpoints considered to be Rank 2 and Rank 3, especially in methods (studies/assays) considered to be at higher Levels. Overall, there is no indication of E, A, or S activity in Rank 1, 2, or 3 endpoints across all assay categories, to suggest that PFHxA disrupts these pathways There was also no indication that PFHxA is a thyroid agonist (Table 9) , with no Rank 1 endpoints, no changes in Rank 2 endpoints, with a change in a Rank 3 endpoint (i.e. reduction in head-to-tail length) in a non-guideline AMA-like study in which no other thyroid endpoints were evaluated (Kim et al., 2015) . However, in evaluating the hypothesis that PFHxA acts as a thyroid antagonist, several Rank 1 endpoints changes were noted (e.g., thyroid weight and histopathology) in one in vivo mammalian study in which a high dose of NaPFHx was administered (Table 10 ). In the one 90-day study in which NaPFHx was administered, there was a change in thyroid weights and histopathology at the highest dose (500 mg/kg/day); specific changes included an increase in the thyroid weight in the high-dose recovery group, and minimal hypertrophy of thyroid follicular epithelium in the high-dosed male and female rats. As highlighted above, these thyroid changes were minimal and proposed to be secondary to the up-regulation of liver metabolic enzymes based on increased liver weights. Also of interest is lack of, or weak interaction of PFHxA with TR or thyroid transport proteins evaluated in vitro (Table 4) . Therefore, given the majority of negative changes in Rank 1 thyroid endpoints together with the lack of changes in the Rank 2 and 3 endpoints in the mammalian studies, no change in plasma T4 levels in chickens exposed to PFHxA (Rank 2 endpoint), along with negative or weak binding of PFHxA to critical T receptors or proteins (considered an initiating event that could lead to altered thyroid function), PFHxA was not considered to cause ED properties in T pathway.
Lines of evidence (LOE) across endocrine pathways (thyroid)
A substance that disrupts an endocrine pathway can be identified according to the following three criteria: (1) specific endocrine activity (e.g., transactivation of the estrogen receptor), (2) adversity of effects (e.g., changes in thyroid weights and histopathology), and (3) a plausible link between endocrine activity and adverse effect based on the fundamental scientific knowledge available (e.g., transactivation of the estrogen receptor, resulting in a decrease in follicle cell count and decreased fertility). Within an adverse outcome pathway (AOP), these LOE are used to identify key events that lead to adverse outcomes associated with an endocrine pathway disruption. The integration of these data in this context of identifying MoA for an adverse response associated with endocrine activity also assists in identifying data gaps. Because the review and ranking of PFHxA data across the E, A, and S pathways suggested no activity, only endpoint data for the T pathway were integrated as LOEs across all three assay categories (i.e., in vitro, in vivo mammalian, and in vivo non-mammalian) to consider potential MoAs and easily identify data gaps (Fig. 3) . Overall there appears to be a lack of, or weak activity for PFHxA showing any induction of adverse outcomes associated with a disruption in the T pathway based on the studies available.
Discussion
PFHxA has been noted by regulatory agencies as the most likely environmental degradant associated with a new class of chemicals (i.e., C6 fluorotelomer acrylate). These C6 chemicals have been proposed as alternatives to traditional oil and water repellents (i.e. C8 fluorotelomer acrylates) used in the garment and carpet industries (USEPA, 2013) . With the replacement of C8 chemistry with C6 chemistry, it is expected that PFHxA enters the environment via multiple pathways (Martin et al., 2003a; . As an example, apparel and carpet applications for C6 chemistry would lead to environmental releases of PFHxA through laundering and landfill disposal scenarios. Given the likely release of PFHxA to the environment, it is important to correctly characterize the toxicology, including potential endocrine modulation, of this compound.
In this WoE analysis, there is no convincing data to suggest that PFHxA has the potential to modulate the hypothalamic-pituitary-gonadal (HPG) axis (Supplementary Data, Appendix B; Tables B1-B13) . PFHxA was investigated in mice and rats in repeated-dose toxicity studies and was not found to be toxic or a selective reproductive or developmental toxicant. It also did not show adverse effects on fertility or neurotoxicity below the general level of systemic toxicity and was not carcinogenic in a rat two-year bioassay. No PFHxA-related alterations in hormone parameters, including estradiol, LH, and testosterone, were observed at week 52 during the 2-year chronic bioassay in rats. Investigations in repeated-dose studies in mammals indicate that endocrine organs/tissues (weights or histopathology) such as testes, ovaries, thyroid, prostate, pituitary, mammary gland, or uterine were not significantly affected. Despite this body of data, there was no indication that any adverse outcomes observed with exposure to PFHxA are based on an endocrine MoA.
There has been a considerable effort in "read-across" of toxicity data for a given chemical from rodents to aquatic vertebrates in recent years (LaLone et al., 2013; Gunnarsson et al., 2008) . Given the similarity of targets across species and the lack of HPG-specific responses in rodent assays with administration of PFHxA, NaPFHx or APFHx (Kirkpatrick, 2005; Loveless et al., 2009; Chengelis et al., 2009; Iwai and Hoberman, 2014; Klaunig et al., 2015) , a dose-dependent HPG-related PFHxA response in an aquatic vertebrate would not be expected. In one in vitro study, there was a report of a weak interaction with the E pathway. Benninghoff et al. (2011) (Table 3 and Supplementary Data, Appendix B, Table B1 ) reported a competitive binding affinity in rainbow trout that was < 0.01% of E2. However, as discussed above, this weak affinity did not translate to an in vivo response reported in the same article FSTRA-like study, VTG was increased, but the increase was not statistically significant relative to controls, in plasma of rainbow trout (no distinction between genders) (14-day) at 250 ppm (Benninghoff et al., 2011) . FSTRA study (OECD 229) (21-day) reported no change in medaka VTG at aqueous concentrations ranging from 10 to 100 mg/L (CERI 2015).
Ovarian weight decrease a (female rodent studies)
No change in rats (Kirkpatrick, 2005; Chengelis et al., 2009; Loveless et al., 2009 ).
Estrous cyclicity (in rodent studies)
No change in rats (Kirkpatrick, 2005) ; Loveless et al., 2009 ).
Ovarian histopathology (female rodent studies)
No abnormalities in rats (Kirkpatrick, 2005; Chengelis et al., 2009; Klaunig et al., 2015; Loveless et al., 2009 ).
Uterus weight (female rodent studies)
No change detected in rats (Chengelis et al., 2009; Loveless et al., 2009 ) and mice (Iwai and Hoberman, 2014) . Testis weight decrease a (male rodent studies)
Uterus histopathology (female rodent studies)
No abnormalities detected in rats (Kirkpatrick, 2005; Chengelis et al., 2009; Klaunig et al., 2015; Loveless et al., 2009 ). Testis histopathology (male rodent studies) No abnormalities in rats (Kirkpatrick, 2005; Chengelis et al., 2009; Klaunig et al., 2015; Loveless et al., 2009 ).
Vaginal histopathology (female rodent studies)
No abnormalities in rats (Chengelis et al., 2009; Klaunig et al., 2015; Loveless et al., 2009) .
ERTA
Negative for ERTA activity in MMV-Luc cells, BGLuc4E2, (hER) and HEK293T cells (Wielogorska et al., 2015; Rosenmai et al., 2016; Behr et al., 2018) .
Epididymis histopathology (male rodent studies)
ERTA and ERBA
Negative activity in 15/15 assays integrated ER binding and transactivation assays (ToxCast/Tox21).
Mammary histopathology (female rodent studies)
No abnormalities in rats (Kirkpatrick, 2005; Chengelis et al., 2009; Klaunig et al., 2015; Loveless et al., 2009) . Prostate histopathology (male rodent studies) No abnormalities in rats (Kirkpatrick, 2005; Chengelis et al., 2009; Klaunig et al., 2015; Loveless et al., 2009) . ERBA Positive (weak) competitive binding to rainbow trout hepatic ER (Benninghoff et al., 2011) .
Steroidogenesis Assay
No changes were detected in 17β-estradiol levels in exposed NCIeH295R cells (Rosenmai et al., 2016; Behr et al., 2018) . FSTRA Fecundity & Fertility FSTRA study (OECD 229) (21-day) reported no significant difference in medaka fecundity or fertility at aqueous concentrations of 10 and 100 mg/L (CERI 2015).
FSTRA -Fish Short-Term Reproduction Assay. VTG -vitellogenin.
a Expected direction of endpoint.
S.J. Borghoff et al. Regulatory Toxicology and Pharmacology 99 (2018) 168-181 as well as in the mammalian in vivo studies. Benninghoff et al. (2011) investigated the ability of PFHxA to alter VTG in rainbow trout after 14 days of dietary exposure to 250 ppm PFHxA. While VTG may appear to be increased, there was no statistically significant difference observed in PFHxA-exposed fish relative to controls. In addition, the VTG increase relative to the study positive control (i.e., 5 ppm E2) was orders of magnitude less. A more recently completed FSTRA reported no significant differences in medaka VTG following 21 days of exposure to Table 6 Ranked endpoints to PFHxA as an estrogen antagonist.
aqueous PFHxA concentrations ranging from 10 to 100 mg/L (CERI 2015). Also integrated into this assessment were the results from the HTS data in the ToxCast/Tox21 database, which demonstrated that PFHxA does not bind or activate the ER, or AR with no bioactivity in 0/15 or 0/ 4 assays conducted, respectively. As such, this ToxCast/Tox21 database together with data from the peer-reviewed literature in which ER and AR binding or receptor transactivation activity was weak to negative, confirmed a lack of activity across both E and A pathways. Also, in the HTS database, aromatase inhibition assay was negative, along with a report in the peer-reviewed literature described by Gorrochategui et al. (2014) that demonstrated lack of PFHxA ability to inhibit aromatase activity in vitro, suggesting no interference in modulating estrogen levels.
The in vitro HTS data captured from the ToxCast/Tox21 database also suggested that PFHxA does not bind or activate the TR, with no bioactivity in nine different assays. An in vitro study by Vongphachan et al. (2011) has been cited as providing evidence of a potential thyroidrelated effect. Unfortunately, the results of this study provided no insight into the potential for a thyroid-related effect associated with PFHxA, because the observed responses were not dose related and occurred only at extremely high concentrations. In addition, the results were not observed in a second bird cell line (Vongphachan et al., 2011) . While the in vitro study described by Weiss et al. (2009) may suggest evidence of thyroid activity, these studies do not provide dose-dependent observations, or observations that PFHxA is a strong agonist/antagonist (i.e., < 1% of T4 binding affinity). Also, in a series of in vitro assays reported by Ren et al. (2015 Ren et al. ( , 2016 , no relevant binding interaction with TR was demonstrated.
A 90-day toxicity study with NaPFHx caused only minimal hypertrophy of thyroid follicular epithelium in male and female rats in the 500 mg/kg/day dose group, and no relevant histological changes were observed in this tissue in a chronic toxicity study in rats with PFHxA up to 200 mg/kg/day. In the one PFHxA in vivo non-mammalian study that specifically investigated the thyroid pathway, Cassone et al. (2012) reported that PFHxA did not alter plasma T4 levels, pipping success, or morphology up to 9700 ng/g in chickens. The lack of any toxicological findings is similar to a chronic bobwhite quail reproductive study with PFHxA (Frey et al., 2010) , in which there were no treatment -related effects (number of eggs laid, egg shell thickness, etc.) at doses ≤ 10,000 mg/kg. While these WoE endocrine evaluations are hazard based (i.e., focus only on the potential to modulate endocrine pathways), it is equally important to incorporate the likely exposure of PFHxA for consideration of the risk to human health and wildlife. In the case of PFHxA, this evaluation demonstrates there no hazard identified either to ecological systems or human health associated with modulation of endocrine activity. However, it is also important to note that exposure levels of PFHxA tend to be low with reported median concentration in surface waters in China at 9.1 ng/L (Wan et al., 2017) , and in the Western Mediterranean Sea at 0.12 ng/L (Brumovský et al., 2016) . Also, levels measured in human plasma has been reported to be below levels of analytical detection in samples collected between 1977 and 2004 (Wilhelm et al., 2009) . A PFHxA quality standard (QS) for drinking water and human health has been calculated to be 1000 ng/L, but no QS could be set for ecological species due to insufficient data (Wilhelm et al., 2010; Valsecchi et al., 2017) . As such it is important to note that the concentrations of PFHxA detected in surface waters (i.e., ppt) are significantly below the levels (i.e., ppm) used in the mammalian and non-mammalian (ecotoxicological) studies in which endocrine activity specific hazards were not identified.
Conclusions
Traditional guideline studies (i.e., OECD), as well as studies with design aspects of the guidelines, have been evaluated for study quality, No rank 1 endpoints in mammalian or non-mammalian studies.
Steroidogenesis Assay
No changes were detected in 17β-estradiol or testosterone levels in exposed NCIeH295R cells. (Rosenmai et al., 2016; Behr et al., 2018) .
Aromatase assay
No inhibitory activity in JEG-3 cells (Gorrochategui et al., 2014) and in MCF-7 (HTS assay) (ToxCast/ Tox21). Ovarian weight (female rodent studies) No change detected in rats (Kirkpatrick, 2005; Chengelis et al., 2009; Loveless et al., 2009 ).
Testis weights (male rodent studies)
No change (Kirkpatrick, 2005; Chengelis et al., 2009; Loveless et al., 2009 ). FSTRA-like-VTG decrease in females a FSTRA-like study, VTG was increased, but not significantly relative to controls in plasma of rainbow trout (no distinction between genders) (14-day) at 250 ppm (Benninghoff et al., 2011) . FSTRA study (OECD 229) (21-day) reported no change in medaka VTG at aqueous concentrations ranging from 10 to 100 mg/L (CERI 2015).
a Expected direction of endpoint. Fig. 3 . LOE for PFHxA thyroid activity across study categories. Activity defined as N, Negative; P, Positive; W, Weak positive, based on an increase only in the recovery group and mild histological changes in the high dose group only.
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Regulatory Toxicology and Pharmacology 99 (2018) [168] [169] [170] [171] [172] [173] [174] [175] [176] [177] [178] [179] [180] [181] relevance, and endpoints that provide information to characterize endocrine disruption potential, with endocrine endpoints ranked and activity evaluated in this WoE analysis of endocrine modulation by PFHxA. Based on the lack of evidence for adverse thyroid effects in both in vivo non-mammalian and mammalian studies (Kirkpatrick, 2005; Loveless et al., 2009; Chengelis et al., 2009; Frey et al., 2010; Benninghoff et al., 2011; Cassone et al., 2012; Iwai and Hoberman, 2014; Kim et al., 2015; Klaunig et al., 2015) , as well as overall lack of evidence that PFHxA binds/activates either the thyroid receptorbinding protein or TR in vitro (Weiss et al., 2009; Ren et al., 2015 Ren et al., , 2016 ; ToxCast/Tox21 Database), there is limited concern that PFHxA interferes in the thyroid pathway in either mammals or wildlife. With respect to studies investigating the potential for PFHxA to modulate the HPG axis, there is no convincing data to suggest that PFHxA has activity in either the mammalian or non-mammalian studies.
